R&D News | pharmaphorum

News

Change at the top of Recursion as co-founder leaves CEO role

After 12 years as CEO of 'techbio' player Recursion, Chris Gibson is switching to the role of chair and will be replaced by Najat Khan.

News

Alkermes breaks new ground in narcolepsy with orexin drug

Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.

News

AI features in UK plan to reduce animal testing

The UK government has set out an ambitious plan to phase out animal testing in scientific studies within five years.

News

FDA appoints veteran Pazdur to replace Tidmarsh

The FDA has steadied the ship at CDER by naming veteran regulator Richard Pazdur as director, although he was reportedly reluctant to take the job.

News

enGene's president and chief executive, Ron Cooper

Trial sets up filing for enGene bladder cancer gene therapy

enGene is hoping to file its gene for a form of bladder cancer before the end of 2026, based on phase 2 data revealing a 62% complete response rate.

News

Daiichi Sankyo launches its STING operation against cancer

Daiichi Sankyo has started clinical testing of a STING agonist for cancer, a class that has been hit by safety issues and discontinued programmes.

Change at the top of Recursion as co-founder leaves CEO role

Alkermes breaks new ground in narcolepsy with orexin drug

AI features in UK plan to reduce animal testing

FDA appoints veteran Pazdur to replace Tidmarsh

Trial sets up filing for enGene bladder cancer gene therapy

Daiichi Sankyo launches its STING operation against cancer

US launches probe of German 'underpayment' for medicines

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks